

DEFINITION

Description:

- Cystitis is an acute infection of the urinary bladder (lower urinary tract) and can occur alone or in conjunction with pyelonephritis.
- This topic refers primarily to infectious cystitis; other urinary tract infections (UTIs) such as pyelonephritis, are addressed in other SRNA CDTs.
- Uncomplicated UTI: occurs in clients who have a normal, unobstructed genitourinary tract, who have no history of recent instrumentation, and whose symptoms are confined to the lower urinary tract. Uncomplicated UTIs are most common in young, sexually active women.
- Complicated UTI: is an infection of the lower or upper urinary tract in the presence of an anatomic abnormality, a functional abnormality, or a urinary catheter.
 - All pregnant females and males are considered to present with complicated UTIs.
- Recurrent UTI: is a symptomatic UTI that follows resolution of an earlier episode, usually after appropriate treatment.
 - No single definition of the frequency of recurrent UTI exists but three or more infections per year are commonly understood to be “recurrent”.
 - Most recurrences are thought to represent reinfection rather than relapse.

IMMEDIATE CONSULTATION REQUIRED IN THE FOLLOWING SITUATIONS

- Gross hematuria
- Temperature > 38°C oral with chills and increased respiration (> 24 resp/minute) and hypotension or hypertension
- Acute abdominal pain
- Immunocompromised client
- New onset edema
- Immediate consultation must take place for any other factor listed under complicated UTI, excluding pregnant females.

CAUSES

- Most UTIs in females are caused by bacteria originating from bowel flora:
 - *Escherichia coli* (*E. coli*) is the causative organism in 80% of cases of uncomplicated cystitis

CYSTITIS ADULT

- *Staphylococcus saprophyticus* accounts for 15% of infections
- Enterobacteriaceae (e.g., Klebsiella, Proteus, Enterobacter, Pseudomonas) also contribute
- Candida is associated with nosocomial UTI
- In males:
 - *E. coli* (80% of infections)
 - Other organisms include: Klebsiella, Enterobacter, Proteus, Pseudomonas, Serratia, *Streptococcus faecalis*, and Staphylococcus spp.

PREDISPOSING AND RISK FACTORS

Female:

- Previous UTI
- Diabetes mellitus
- Pregnancy
- Sexual activity
- Use of spermicides or diaphragm
- Underlying abnormalities of the urinary tract such as tumours, calculi, strictures, incomplete bladder emptying, urinary incontinence, neurogenic bladder
- Catheterization
- Recent antibiotic use
- Poor hygiene
- Estrogen deficiency
- Inadequate fluid intake

Male:

- Benign prostatic hypertrophy (BPH)
- Cognitive impairment
- Fecal incontinence
- Urinary incontinence
- Anal intercourse
- Recent urological surgery, catheterization
- Infection of the prostate or kidney
- Urinary tract instrumentation
- Immunocompromised
- Outlet obstruction

CYSTITIS ADULT

HISTORY

Female (any or all may be present):

- Burning during urination
- Dysuria (painful or difficult urination)
- Urgency (a sudden almost uncontrollable need to urinate)
- Frequency
- Sensation of incomplete bladder emptying
- Blood in urine
- Lower abdominal pain or cramping
- Offensive odour of urine
- Nocturia
- Sudden onset of urinary incontinence
- Low back pain

Male:

- Enquire as to all of the above symptoms plus symptoms that may indicate prostatitis, such as:
 - Hesitancy
 - Slow urinary stream
 - Dribbling of urine
 - Nocturia
- Suprapubic tenderness and urethral discomfort

PHYSICAL FINDINGS

There may be no physical findings in cystitis.

Female:

- Suprapubic tenderness
- Urethral or vaginal tenderness
- Fever or costovertebral angle tenderness indicates upper UTI

Male:

- Systemic symptoms (e.g., chills, fever) present with concomitant pyelonephritis or prostatitis

CYSTITIS ADULT

DIFFERENTIAL DIAGNOSIS

Female:

- Vaginitis
- Asymptomatic bacteriuria
- Sexually transmitted infections (STIs) causing urethritis or pyuria
- Hematuria from causes other than infection (e.g., neoplasm, calculi)
- Interstitial cystitis
- Psychological dysfunction

Male:

- Anatomic or functional pathology
- Urethritis/STIs
- Infection in other sites of the genitourinary tract (e.g., epididymis)
- Prostate disorders (e.g., BPH, prostatitis)

COMPLICATIONS

Female:

- Pyelonephritis or sepsis
- Renal abscess
- Acute urinary outlet obstruction
- Pregnant females are at higher risk of pyelonephritis
- Recurrent infection

Male:

- Pyelonephritis or sepsis
- Renal abscess
- Acute urinary outlet obstruction
- Recurrent infection

INVESTIGATIONS AND DIAGNOSTIC TESTS

Female and Male:

- Dipstick urinalysis:
 - Leukocyte esterase
 - Nitrite tests are useful with nitrite-producing organisms (e.g., Enterococci, *S. saprophyticus*, Acinetobacter, Chlamydia)

CYSTITIS ADULT

- Urine culture: only indicated if diagnosis is unclear or client has recurrent infections (> 3 infections per year) and resistance is suspected. Other situations where urine culture is recommended include:
 - All males
 - All pregnant females
 - Elderly women
 - Those with indwelling catheters
- Consider differentiating UTI from STI based on history and risk factors, and if present, test and treat for Chlamydia and *Neisseria gonorrhoeae*.

MAKING THE DIAGNOSIS

Female:

- Presumptive diagnosis of UTI can be made if either:
 - Dysuria and frequency are present
 - Dipstick urinalysis shows positive result for nitrite or positive leukocyte esterase
- Women with recurrent UTI may accurately self-diagnose UTI
- Elderly clients with UTIs may present with atypical symptoms

Male:

- UTIs are less common in males. Alternate diagnoses should be considered.
- As stated above, all males presenting with symptoms of UTI should have a urine culture performed.

MANAGEMENT AND INTERVENTIONS

Goals of Treatment

Female and Male:

- Relieve symptoms of acute infection
- Prevent ascending infection
- Prevent recurrent infection
- Prevent complications

Non-Pharmacological Interventions

- Drink plenty of water and other fluids every day (8-10 glasses)

CYSTITIS ADULT

- Empty bladder as soon as urge is felt
- Females should wipe from front to back after using the toilet
- Try to void before, and as soon after, intercourse

Pharmacological Interventions

Uncomplicated UTI (most common in young, sexually active women)

- Nitrofurantoin (Macrobid) 100 mg orally q12h for 5 days
- Sulfamethoxazole/Trimethoprim (SMX/TMP) 400/80 2 tabs orally q12h for 3 days or 800/160 (DS) 1 tab orally q12h for 3 days in areas where *E. coli* resistance is < 20%
- Fosfomycin 3 g orally one dose

Complicated UTI (includes males, excluding pregnant females)

- Consult with a physician/RN(NP)

Pregnant Women:

- Cephalexin 250-500 mg orally q6h for 7 days
- Amoxicillin 500 mg orally q8h for 7 days
- ** Nitrofurantoin (Macrobid) 100 mg orally q12h for 7 days
- Fosfomycin 3 g orally one dose

**Nitrofurantoin is contraindicated in pregnant clients at term (36-42 weeks' gestation) and during labour.

Male:

Consultation with a physician/RN(NP) should take place prior to treatment. Some options the physician/RN(NP) may recommend include the following:

- SMX/TMP 400/80 2 tabs orally q12h or 800/160 (DS) 1 tab orally q12h for 7-10 days
- Nitrofurantoin (Macrobid) 100 mg orally q12h for 7-10 days
- Ciprofloxacin 500 mg orally q12h for 7-10 days

Client and Caregiver Information

- Counsel client about appropriate use of medications (dose, frequency, side effects, the need to complete entire course of treatment, etc.).

SASKATCHEWAN REGISTERED NURSES' ASSOCIATION

RNs WITH ADDITIONAL AUTHORIZED PRACTICE CLINICAL DECISION TOOL DECEMBER 1, 2016

CYSTITIS ADULT

- Instruct client in proper perineal hygiene (wiping from front to back) to prevent recurrence.
- If a catheter is present, consult a physician/RN(NP) for guidance.

Monitoring and Follow-up

- First or rare UTI: in young or middle-aged non-pregnant females, no follow-up is required if cured after antibiotic therapy.

Referral

- All who present with the criteria listed in the “Immediate Consultation Required in the Following Situations” section
- Anyone who does not respond to listed antibiotic treatment
- Recurrent UTI
- Males

DOCUMENTATION

- As per employer policy

REFERENCES

- Anti-infective Review Panel. (2013). *Anti-infective guidelines for community-acquired infections*. Toronto: MUMS Guideline Clearinghouse.
- Colgan, R., & Williams, M. (2011). Diagnosis and treatment of acute uncomplicated cystitis. *American Family Physician, 84*(7), 771–776.
- Das, A., & Gomella, L. G. (2014). *Urinary tract infection in females; Urinary tract infections in males*. In Lexicomp 5-Minute Clinical Consult. Retrieved from Lexi-Comp Inc. Hudson, OH.
- Haddock, G. (2015). Improving the management of urinary tract infection. *Nursing & Residential Care, 17*(1), 22–25.
- Health Canada. (2011). *First Nations and Inuit health: Clinical practice guidelines for nurses in primary care*. Ottawa, ON: Author. Retrieved from <http://www.hc-sc.gc.ca>

SASKATCHEWAN REGISTERED NURSES' ASSOCIATION

RNs WITH ADDITIONAL AUTHORIZED PRACTICE
CLINICAL DECISION TOOL
DECEMBER 1, 2016

CYSTITIS ADULT

Rx Files Academic Detailing Program. (2014). *Rx Files: Drug comparison charts* (10th ed.). Saskatoon, SK: Saskatoon Health Region.

Umeed, M. (2012). Take home messages in the management of cystitis. *Practice Nurse*, 42(12), 13–16.

NOTICE OF INTENDED USE OF THIS CLINICAL DECISION TOOL

This SRNA Clinical Decision Tool (CDT) exists solely for use in Saskatchewan by an RN with additional authorized practice as granted by the SRNA. The CDT is current as of the date of its publication and updated every three years or as needed. A member must notify the SRNA if there has been a change in best practice regarding the CDT. This CDT does not relieve the RN with additional practice qualifications from exercising sound professional RN judgment and responsibility to deliver safe, competent, ethical and culturally appropriate RN services. The RN must consult a physician/RN(NP) when clients' needs necessitate deviation from the CDT. While the SRNA has made every effort to ensure the CDT provides accurate and expert information and guidance, it is impossible to predict the circumstances in which it may be used. Accordingly, to the extent permitted by law, the SRNA shall not be held liable to any person or entity with respect to any loss or damage caused by what is contained or left out of this CDT.

SRNA © This CDT is to be reproduced only with the authorization of the SRNA.